Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

@inproceedings{Chang2014PhaseIS,
  title={Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients},
  author={T. C. Chang and H. S. Shiah and C. H. Yang and Kun-Huei Yeh and Ann Lii Cheng and Bei-fen Shen and Y. W. Wang and C. Grace Yeh and N. J. Chiang and J. Y. Chang and L. T. Tai-Hua Chen},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2014}
}
To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. Patients were enrolled in cohorts of one to three to receive escalating dose of PEP02 in a phase I trial. PEP02, from 60 to 180 mg/m2, was given as a 90-min intravenous infusion, every 3 weeks. A total of 11 patients were enrolled into three dose levels: 60 (one patient), 120 (six patients) and… CONTINUE READING
12 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: results of CALGB 80402 [abstract 4109

  • AJ Ocean, D Niedzwiecki, +5 authors RM Goldberg
  • ASCO annual meeting
  • 2008
1 Excerpt

Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): safety, pharmacogenomics, pharmacokinetics, and tumor response [abstract 2017

  • EH Kraut, MN Fishman, +7 authors JL Steinberg
  • ASCO annual meeting
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…